🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07462481
Recruiting Not applicable

Probiotic Improve Constipation

NCT07462481 · tracked via the Priya Life Science China tracker
Sponsor
Wecare Probiotics Co., Ltd.
Phase
Not applicable
Started
2026-06-10
Last updated
2026-06-09

Condition(s) studied

Constipation

Investigational drug(s) / intervention(s)

ProbioticPlaceboHigh-activity probiotic probiotic

Probiotic: The intervention period of this study will last for 8 weeks (56 days), during which each participant will attend three study visits scheduled at baseline (Week 0), Week 4, and Week 8.

Placebo: The intervention period of this study will last for 8 weeks (56 days), during which each participant will attend three study visits scheduled at baseline (Week 0), Week 4, and Week 8.

High-activity probiotic probiotic: The intervention period of this study will last for 8 weeks (56 days), during which each participant will attend three study visits scheduled at baseline (Week 0), Week 4, and Week 8.

Study summary

To evaluate the efficacy and safety of probiotic as a food supplement in regulating bowel habits in patients with chronic constipation, and to compare it with placebo.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: (1) Age 18-65 years; (2) Constipated patients (less than 3 bowel movements per week and/or Bristol Scale type 1 and 2); (3) Able to complete the study according to the trial protocol; (4) Patients who have signed the informed consent form; (5) Study participants (including male study participants) have no plans to have children within 14 days prior to screening and within 6 months after the end of the trial and voluntarily use effective contraception. \- Exclusion Criteria: 1. Those who have taken a substance with a similar function to the test subject in a short period of time, affecting their judgment of the results; 2. Patients who changed their diet during the study; 3. Patients with severe allergies and immunodeficiency; 4. Pregnant, breastfeeding, or women planning to become pregnant; 5. Those with severe diseases of vital organs such as the cardiovascular system, lungs, liver, and kidneys, diabetes, thyroid disease, severe metabolic diseases, malignant tumors, or severe immune system diseases; 6. Those who have used antibiotics in the past two weeks; 7. Those with severe psychological or mental illnesses; 8. Those who did not consume the test sample as required or did not follow up on time, resulting in the inability to determine the efficacy; 9. Other study participants deemed unsuitable by the researchers. -

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Suzhou Ninth People's Hospital Suzhou Jiangsu Recruiting

More Wecare Probiotics Co., Ltd. trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07462481 on ClinicalTrials.gov ↗ ← All trials in China